Colchicine does not raise blood sugar. The available clinical evidence consistently points in the opposite direction: colchicine appears to modestly lower blood sugar levels, both fasting and after meals. If you take colchicine for gout or heart disease and you’re worried about your glucose, this medication is unlikely to be the culprit.
What Clinical Studies Show
A clinical trial in patients with type 2 diabetes found that colchicine at a dose of 0.5 mg three times daily significantly reduced both fasting and post-meal blood glucose levels, with no adverse effects from the therapy. The researchers concluded that colchicine has anti-diabetic properties.
A separate trial compared colchicine (0.5 mg twice daily) head-to-head with metformin in 150 newly diagnosed type 2 diabetes patients. Both colchicine and metformin reduced HbA1c, a marker of long-term blood sugar control, with statistically significant results. That’s a striking finding: colchicine, a drug designed for inflammation, performed comparably to one of the most widely prescribed diabetes medications.
The largest dataset comes from the LoDoCo2 trial, which followed 5,522 patients with chronic coronary artery disease for a median of about 28 months. Patients taking low-dose colchicine (0.5 mg once daily) developed new-onset type 2 diabetes at a rate of 1.5%, compared to 2.2% in the placebo group. That difference wasn’t statistically significant, meaning it could be due to chance, but it’s notable that the trend went in the favorable direction. Colchicine certainly wasn’t pushing people toward diabetes.
Why Colchicine May Improve Blood Sugar
The explanation lies in inflammation. Chronic, low-grade inflammation is one of the key drivers of insulin resistance, particularly in people who carry excess weight. In fat tissue, immune cells assemble a protein complex called the NLRP3 inflammasome, which triggers a cascade of inflammatory signals. Those signals interfere with how your cells respond to insulin. Specifically, inflammatory molecules activate enzymes in muscle, fat, and liver tissue that disable a critical relay in the insulin signaling chain. The result: your cells stop responding efficiently to insulin, and blood sugar rises.
Colchicine disrupts this process at its source. It works by blocking the internal scaffolding (called microtubules) that cells need to assemble the NLRP3 inflammasome in the first place. Without that assembly, the downstream flood of inflammatory signals is dampened. Animal research reinforces this: mice genetically engineered to lack components of the NLRP3 inflammasome don’t develop insulin resistance even on a high-fat diet. Colchicine essentially mimics that protection pharmacologically.
This anti-inflammatory effect also reduces levels of several specific molecules that worsen metabolic health, including ones that amplify each other in a self-reinforcing loop. By interrupting that loop, colchicine may help restore normal insulin signaling in tissues that had become resistant.
Colchicine and Diabetes Medications
If you take both colchicine and diabetes medications, there’s no known direct interaction that would destabilize your blood sugar control. Colchicine is processed in the liver through a specific enzyme pathway (CYP3A4), the same one used by statins and certain blood pressure medications. Competition for that pathway can increase blood levels of those drugs, potentially raising the risk of side effects. However, common diabetes medications like metformin use different metabolic pathways and aren’t affected in this way.
The trial that compared colchicine and metformin side by side found no safety concerns with colchicine’s glucose-lowering effects. If anything, the combination of colchicine’s anti-inflammatory action and a standard diabetes regimen could work in complementary directions, though this hasn’t been studied as a formal treatment strategy.
Who Might Benefit Most
The blood sugar effects of colchicine are most relevant for people whose metabolic problems are driven by chronic inflammation, a group that includes many people with obesity, metabolic syndrome, or early type 2 diabetes. In these individuals, the NLRP3 inflammasome is highly active in fat tissue, creating a persistent inflammatory state that worsens insulin resistance over time. Colchicine targets exactly that mechanism.
For people with well-controlled blood sugar and no metabolic issues, colchicine’s effect on glucose is likely minimal. The drug isn’t being prescribed as a diabetes treatment. But if you’re taking it for gout or cardiovascular protection and you also happen to have blood sugar concerns, the evidence suggests colchicine is working in your favor on that front, not against you.